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Abstract	  Prostate	  cancer	  is	  the	  most	  common	  cancer	  in	  men,	  resulting	  in	  over	  10,000	  deaths	  per	  year	  in	  the	  UK.	  	  Sequencing	  and	  copy	  number	  analysis	  of	  primary	  tumours	  has	  revealed	  heterogeneity	  within	  tumours	  and	  an	  absence	  of	  recurrent	  founder	  mutations,	  consistent	  with	  non-­‐genetic	  disease	  initiating	  events.	  	  Using	  methylation	  profiling	  in	  a	  series	  of	  multi-­‐focal	  prostate	  tumours	  we	  identify	  promoter	  methylation	  of	  the	  transcription	  factor	  HES5	  as	  an	  early	  event	  in	  prostate	  tumourigenesis.	  We	  confirm	  that	  this	  epigenetic	  alteration	  occurs	  in	  86-­‐97%	  of	  cases	  in	  two	  independent	  prostate	  cancer	  cohorts	  (n=49	  and	  n=39	  tumour-­‐normal	  pairs).	  	  Treatment	  of	  prostate	  cancer	  cells	  with	  the	  demethylating	  agent	  5-­‐aza-­‐2ʹ′-­‐deoxycytidine	  increased	  HES5	  expression	  and	  down-­‐regulated	  its	  transcriptional	  target	  HES6,	  consistent	  with	  functional	  silencing	  of	  the	  HES5	  gene	  in	  prostate	  cancer.	  	  Finally	  we	  identify	  and	  test	  a	  transcriptional	  module	  involving	  the	  AR,	  ERG,	  HES1	  and	  HES6	  and	  propose	  a	  model	  for	  the	  impact	  of	  HES5	  silencing	  on	  tumourigenesis	  as	  a	  starting	  point	  for	  future	  functional	  studies.	  	  	  	   	  
Introduction	  	  Current	  analysis	  of	  cancer	  genome	  sequencing	  has	  revealed	  disease	  processes	  and	  genomic	  alterations	  that	  may	  underlie	  disease	  initiation	  or	  evolution	  (Baca,	  et	  al.	  2013;	  Nik-­‐Zainal,	  et	  al.	  2012;	  Tarpey,	  et	  al.	  2013).	  	  These	  approaches	  have	  identified	  and	  enumerated	  recurrently	  mutated	  driver	  genes	  in	  several	  cancer	  types,	  such	  as	  KRAS	  which	  is	  mutated	  in	  93%	  of	  pancreatic	  cancers	  (Biankin,	  et	  al.	  2012)	  and	  TP53	  which	  is	  mutated	  in	  96%	  of	  high	  grade	  serous	  ovarian	  cancers	  (2011),	  69%	  of	  oesophageal	  cancer	  (Weaver,	  et	  al.	  2014)	  and	  over	  50%	  of	  colorectal	  cancers	  (2012).	  	  In	  contrast	  with	  these	  highly	  recurrent	  mutations	  a	  recent	  study	  of	  112	  aggressive	  primary	  prostate	  cancers	  reported	  that	  the	  most	  significantly	  mutated	  gene	  (SPOP)	  was	  altered	  in	  only	  13%	  of	  cases,	  with	  the	  next	  most	  commonly	  affected	  gene	  TP53	  affected	  in	  only	  6%	  of	  prostate	  tumours	  (Barbieri,	  et	  al.	  2012).	  	  	  	  Therefore,	  while	  genome	  sequencing	  approaches	  have	  provided	  important	  insights	  into	  the	  biology	  of	  prostate	  cancer	  (Baca	  et	  al.	  2013;	  Berger,	  et	  al.	  2011;	  Lindberg,	  et	  al.	  2013;	  Weischenfeldt,	  et	  al.	  2013)	  the	  high	  intra-­‐	  and	  inter-­‐tumour	  heterogeneity	  coupled	  with	  the	  small	  samples	  sizes	  may	  have	  limited	  the	  identification	  of	  genetic	  driver	  events	  in	  primary	  tumours.	  	  Indeed	  previous	  genome	  sequencing	  studies	  have	  reported	  few	  common	  mutations	  between	  different	  tumour	  foci	  within	  the	  same	  prostate	  (Lindberg	  et	  al.	  2013),	  highlighting	  marked	  intra-­‐tumour	  heterogeneity	  and	  the	  absence	  of	  a	  genetic	  founder	  mutation.	  	  This	  complexity	  has	  led	  many	  groups	  to	  focus	  on	  late	  stage,	  aggressive	  disease	  with	  the	  aim	  of	  identifying	  genomic	  events	  associated	  with	  disease	  progression	  (Barbieri	  et	  al.	  2012;	  Grasso,	  et	  al.	  2012).	  	  However,	  their	  remain	  important	  unanswered	  questions	  over	  the	  early	  stages	  of	  prostate	  tumour	  evolution	  where	  genetic	  events	  appear	  to	  be	  for	  the	  most	  part	  heterogeneous.	  	  One	  notable	  exception	  to	  this	  are	  gene	  fusions	  involving	  ETS	  transcription	  factors	  that	  have	  been	  found	  to	  occur	  in	  approximately	  half	  of	  all	  prostate	  cancers	  (Perner,	  et	  al.	  2006;	  Tomlins,	  et	  al.	  2005).	  	  However,	  these	  androgen	  receptor	  (AR)	  driven	  gene	  fusions	  alone	  are	  insufficient	  to	  initiate	  prostate	  tumours	  in	  disease	  models	  (Carver,	  et	  al.	  2009;	  Chen,	  et	  al.	  2013)	  and	  may	  not	  be	  early	  ‘founder’	  events	  in	  disease	  evolution	  (Barry,	  et	  al.	  2007;	  Mertz,	  et	  al.	  2013;	  Minner,	  et	  al.	  2013).	  	  	  	  Therefore	  current	  evidence	  would	  seem	  to	  suggest	  that	  if	  a	  common	  initiating	  driver	  event	  exists	  it	  is	  not	  genetic,	  implicating	  other	  mechanisms	  in	  disease	  aetiology.	  	  In	  addition	  to	  somatic	  mutation	  several	  other	  disease-­‐initiating	  pathways	  have	  been	  proposed	  in	  prostate	  cancer	  including	  germline	  predisposition	  (Eeles,	  et	  al.	  2013;	  Kote-­‐Jarai,	  et	  al.	  2011),	  telomere	  shortening	  (Heaphy,	  et	  al.	  2013;	  Sommerfeld,	  et	  al.	  1996),	  chronic	  inflammation	  (Caini,	  et	  al.	  2014;	  Elkahwaji,	  et	  al.	  2009),	  metabolic	  stress	  (Freedland	  2005;	  Kalaany	  and	  Sabatini	  2009)	  and	  epigenetic	  alterations	  (Kanwal,	  et	  al.	  2014;	  Lee,	  et	  al.	  1994).	  	  It	  is	  likely	  that	  non-­‐genetic	  and	  genetic	  alterations	  interact	  during	  tumourigenesis	  and	  several	  studies	  have	  identified	  interactions	  between	  somatic	  mutations	  and	  micro-­‐environmental	  changes	  (Garcia,	  et	  al.	  2014),	  inflammation	  (Kwon,	  et	  al.	  2014)	  and	  metabolism	  (Kalaany	  and	  Sabatini	  2009).	  	  Current	  technologies	  allow	  accurate	  identification	  and	  quantification	  of	  epigenetic	  
alterations	  and	  are	  therefore	  a	  tractable	  second	  line	  of	  enquiry	  to	  identify	  driver	  events	  in	  prostate	  tumourigenesis.	  	  	  We	  have	  recently	  identified	  a	  role	  for	  the	  enhancer	  of	  split	  transcription	  factor	  HES6	  in	  prostate	  cancer	  and	  AR	  signaling	  (Ramos-­‐Montoya,	  et	  al.	  2014).	  	  Herein	  we	  characterize	  an	  epigenetic	  alteration	  at	  the	  promoter	  of	  the	  related	  HES5	  gene,	  which	  was	  recently	  reported	  in	  a	  panel	  of	  genes	  that	  showed	  promise	  as	  a	  prostate	  cancer	  marker	  in	  biopsy	  samples	  (Paziewska,	  et	  al.	  2014).	  	  We	  profile	  this	  change	  in	  detail	  and	  show	  it	  to	  be	  an	  early	  event	  in	  prostate	  cancer	  development	  and	  highly	  recurrent	  across	  three	  unrelated	  prostate	  tumour	  cohorts.	  	  	  We	  then	  characterize	  an	  interaction	  between	  the	  epigenetic	  silencing	  of	  HES5	  and	  the	  expression	  of	  HES6	  and	  provide	  evidence	  for	  interactions	  with	  known	  oncogenic	  pathways	  in	  prostate	  cancer	  (namely	  AR	  signaling	  and	  ERG	  gene-­‐fusions),	  highlighting	  a	  transcriptional	  network	  that	  is	  altered	  in	  prostate	  cancer	  development	  first	  by	  an	  epigenetic	  change	  and	  then	  by	  a	  genomic	  rearrangement.	  	  	  	  
Materials	  and	  methods	  
	  
Sample	  cohorts	  In	  a	  series	  of	  four	  radical	  prostatectomy	  specimens	  we	  systematically	  dissected	  the	  whole	  prostates,	  identified	  regions	  containing	  tumour	  and	  harvested	  seventeen	  tumour-­‐rich	  samples	  from	  thirteen	  spatially	  separated	  tumour	  cores	  (median	  46%	  tumour,	  IQR	  36-­‐62%),	  four	  adjacent	  benign	  samples	  and	  three	  whole	  blood	  samples	  (Figure	  1a	  and	  Supplementary	  Figure	  1a).	  Each	  tumour	  core	  was	  taken	  from	  a	  5mm	  tissue	  slice	  and	  the	  tumour	  content	  of	  samples	  used	  for	  DNA	  extraction	  was	  assessed	  by	  a	  Pathologist	  using	  H&E	  staining	  of	  immediately	  adjacent	  sections	  (Warren,	  et	  al.	  2013).	  	  From	  two	  such	  cores	  we	  also	  took	  three	  sets	  of	  sections	  for	  DNA	  extraction	  to	  allow	  assessment	  of	  heterogeneity	  within	  cores	  in	  addition	  to	  the	  spatial	  heterogeneity	  within	  and	  between	  cancerous	  prostates	  (Supplementary	  Figure	  1a).	  	  These	  samples	  were	  used	  for	  global	  methylation	  profiling	  using	  Infinium	  HumanMethylation450	  arrays	  (see	  below	  for	  details).	  	  In	  a	  separate	  cohort	  of	  39	  matched	  prostate	  tumour	  and	  adjacent	  benign	  samples	  we	  performed	  targeted	  bisulfite	  sequencing	  of	  the	  HES5	  promoter,	  to	  assess	  the	  frequency	  of	  HES5	  hypermethylation	  in	  prostate	  cancer.	  	  This	  analysis	  provides	  a	  promoter-­‐wide	  view	  of	  DNA	  methylation	  changes	  at	  the	  HES5	  promoter	  (in	  contrast	  to	  the	  limited	  number	  of	  CpGs	  assessed	  using	  methylation	  profiling	  arrays).	  	  In	  an	  unrelated,	  larger	  cohort	  of	  prostate	  cancers	  with	  publicly	  available	  methylation	  array	  data	  (n=304	  tumours,	  n=49	  matched	  normal	  samples)	  (Weinstein,	  et	  al.	  2013)	  we	  assessed	  the	  recurrence	  of	  HES5	  promoter	  methylation.	  	  	  	  	  
DNA	  methylation	  	  profiling	  in	  blood,	  benign	  prostate	  and	  multiple	  spatially	  
separate	  tumour	  foci	  Clinical	  samples	  for	  analysis	  were	  collected	  from	  prostatectomy	  patients	  with	  full	  research	  consent	  at	  the	  Addenbrooke’s	  Hospital,	  Cambridge,	  UK.	  Prostates	  were	  sliced	  and	  processed	  as	  described	  previously	  (Warren	  et	  al.	  2013).	  A	  single	  5mm	  slice	  of	  the	  prostate	  was	  selected	  for	  research	  purposes.	  Tissue	  cores	  of	  4mm	  or	  6mm	  were	  taken	  from	  the	  slice	  and	  frozen.	  Frozen	  cores	  were	  mounted	  vertically	  and	  sectioned	  transversely	  giving	  a	  single	  5µm	  frozen	  section	  for	  H&E	  staining	  followed	  by	  6x50µm	  sections	  for	  DNA	  preparation	  using	  the	  Qiagen	  Allprep	  kit.	  Using	  the	  Infinium	  HumanMethylation450	  BeadChip	  Kit	  DNA	  was	  subjected	  to	  bisulfite	  conversion,	  amplification,	  fragmentation,	  hybridization,	  extension	  and	  labeling	  according	  to	  the	  manufacturers	  instructions	  (Illumina,	  UK).	  	  Bead	  summary	  data	  from	  Infinium	  HumanMethylation450	  arrays	  were	  processed	  using	  the	  Minfi	  package	  in	  the	  R	  statistical	  software	  (Aryee,	  et	  al.	  2014;	  R-Core-Team	  2014).	  	  As	  previously	  described	  probe	  types	  were	  normalized	  separately	  (Marabita,	  et	  al.	  2013)	  before	  generating	  M-­‐values	  and	  B-­‐values	  for	  exploratory	  analysis.	  	  Summary	  plots	  were	  generated	  in	  the	  R	  statistical	  software	  (R-Core-Team	  2014).	  	  Raw	  and	  processed	  data	  have	  been	  uploaded	  to	  the	  ArrayExpress	  portal	  under	  accession	  E-­‐MTAB-­‐2964,	  in	  addition	  all	  code	  used	  to	  generate	  figures	  in	  the	  paper	  are	  included	  as	  part	  of	  the	  R-­‐markdown	  HTML	  document	  in	  Supplementary	  Material	  2.	  	  
Targeted	  bisulfite	  sequencing	  PCR	  primers	  were	  designed	  to	  amplify	  a	  441bp	  fragment	  from	  the	  HES5	  promoter	  containing	  60	  CpGs	  (HES5-­‐BSx-­‐F:	  5’-­‐GAGGGGGTGTTAGGTTGGTT-­‐3’;	  HES5-­‐BSx-­‐R:	  5’-­‐ACCCACCTACTCCTTAAAAAAC-­‐3’).	  	  Amplicons	  were	  generated	  separately	  for	  39	  matched	  tumour	  normal	  sample	  pairs	  and	  assessed	  before	  preparing	  barcoded	  sequencing	  libraries	  using	  a	  Nextera	  XT	  kit	  (Illumina,	  UK).	  	  Barcoded	  DNAs	  were	  quantified	  and	  equal	  amounts	  of	  each	  indexed	  library	  were	  then	  pooled	  and	  sequenced	  on	  an	  Illumina	  MiSeq	  (PE300).	  	  Fastq	  data	  files	  were	  split	  using	  index	  sequences	  and	  downstream	  methylation	  analysis	  was	  performed	  using	  Bismark	  (Krueger	  and	  Andrews	  2011)	  and	  summary	  plots	  and	  test	  statistics	  were	  generated	  in	  the	  R	  statistical	  software	  (R-Core-Team	  2014).	  	  This	  analysis	  gave	  a	  median	  sequencing	  coverage	  of	  786x	  (Supplementary	  
Figure	  3).	  	  	  All	  code	  used	  to	  generate	  figures	  in	  the	  paper	  are	  included	  as	  part	  of	  the	  R-­‐markdown	  HTML	  document	  in	  Supplementary	  Material	  2.	  	  	  
	  
Data	  mining	  An	  R	  markdown	  document	  containing	  all	  code	  required	  to	  reproduce	  our	  analysis	  and	  all	  figures	  has	  been	  included	  as	  a	  supplementary	  HTML	  document	  (Supplementary	  Material	  2).	  	  Briefly,	  DNA	  methylation	  450k	  array	  data	  for	  LNCaP	  prostate	  cancer	  cells	  and	  PrEC	  benign	  prostate	  epithelial	  cells	  (CC-­‐2555,	  Lonza)	  were	  obtained	  from	  GEO	  (triplicate	  data	  for	  each	  cell	  line	  from	  GSE34340	  and	  singleton	  data	  for	  each	  cell	  line	  from	  GSE40699)	  (Statham,	  et	  al.	  2012;	  Varley,	  et	  al.	  2013)	  and	  summary	  plots	  were	  generated	  using	  the	  R	  statistical	  software	  (R-Core-Team	  2014).	  	  Gene	  expression	  data	  from	  LNCaP	  cells	  treated	  with	  the	  demethylating	  agent	  5-­‐aza-­‐2′-­‐deoxycytidine	  were	  retrieved	  from	  GEO	  (GSE25346).	  Gene	  expression	  data	  from	  human	  prostate	  benign	  and	  tumour	  tissues	  were	  obtained	  from	  GEO	  (GSE3325).	  Gene	  expression	  data	  from	  control	  
and	  ERG-­‐knockdown	  VCaP	  cells	  was	  retrieved	  from	  GEO	  (GSE60771).	  	  All	  GEO	  data	  were	  retrieved	  using	  the	  GEOquery	  package	  in	  the	  R	  statistical	  software	  and	  summary	  plots	  were	  generated	  using	  the	  same	  software	  (Davis	  and	  Meltzer	  2007;	  R-Core-Team	  2014).	  	  Transcriptional	  networks	  were	  drawn	  using	  the	  BioTapestry	  application	  (Longabaugh	  2012)	  constructing	  models	  using	  ChIP-­‐seq	  binding	  profiles,	  expression	  correlations	  and	  published	  transcriptional	  links.	  	  
HES5	  motif	  enrichment	  analysis	  The	  position	  weight	  matrix	  for	  HES5	  was	  obtained	  from	  Yan,	  et	  al	  2013	  (Yan,	  et	  al.	  2013)	  and	  used	  to	  search	  the	  genomic	  sequence	  of	  the	  HES6	  gene	  locus	  (including	  1kb	  upstream	  and	  1kb	  downstream	  sequence).	  	  Motif	  searches	  were	  carried	  out	  using	  the	  RSAT	  matrix-­‐scan	  (with	  human	  ‘upstream-­‐noorf’	  background	  control)	  (Turatsinze,	  et	  al.	  2008)	  and	  motif	  scores	  were	  visualized	  using	  BioSAVE	  (Pollock	  and	  Adryan	  2008).	  
	  
Androgen	  time-­‐course	  gene	  expression	  profiling	  in	  LNCaP	  and	  VCaP	  cells	  Following	  72hr	  steroid	  depletion	  in	  media	  containing	  10%	  charcoal	  stripped	  FBS	  LNCaP	  and	  VCaP	  cells	  were	  subjected	  to	  androgen	  stimulation	  (1nM	  R1881)	  or	  vehicle	  control	  treatment	  (0.01%	  ethanol).	  	  Cells	  were	  harvested	  at	  the	  indicated	  time-­‐points	  over	  a	  24h	  period	  following	  treatment	  and	  RNA	  extracted	  using	  Trizol	  (Life	  Technologies).	  	  For	  the	  LNCaP	  treatment	  time-­‐course	  a	  full	  analysis	  has	  been	  published	  (Massie,	  et	  al.	  2011)	  and	  raw	  and	  normalized	  data	  have	  been	  deposited	  at	  GEO	  (GSE18684).	  	  Data	  for	  the	  VCaP	  androgen	  treatment	  time-­‐course	  have	  also	  been	  deposited	  at	  ArrayExpress	  (E-­‐MTAB-­‐2968).	  	  Expression	  data	  were	  analysed	  using	  the	  beadarray	  software,	  with	  spatial	  artefacts	  identified	  and	  removed	  automatically	  (BASH)	  and	  curated	  manually	  (Cairns,	  et	  al.	  2008;	  Dunning,	  et	  al.	  2007).	  The	  resulting	  data	  set	  was	  summarized	  with	  outliers	  removed	  to	  obtain	  mean	  log-­‐intensity	  and	  standard	  error	  for	  each	  probe/array	  combination.	  	  	  	  	  
Results	  
	  
HES5	  promoter	  methylation	  is	  an	  early	  event	  in	  prostate	  tumourigenesis	  In	  order	  to	  investigate	  the	  epigenetic	  landscape	  within	  and	  between	  prostate	  tumours	  we	  systematically	  dissected	  four	  radical	  prostatectomy	  specimens,	  harvesting	  seventeen	  tumour-­‐rich	  samples	  from	  thirteen	  spatially	  separated	  tumour	  cores	  (median	  46%	  tumour,	  IQR	  36-­‐62%),	  four	  adjacent	  benign	  samples	  and	  three	  whole	  blood	  samples	  (Figure	  1a	  and	  Supplementary	  Figure	  1a).	  Consistent	  with	  previous	  reports	  (Lindberg	  et	  al.	  2013)	  these	  spatially	  separated	  tumour	  cores	  appeared	  to	  be	  only	  distantly	  related	  by	  somatic	  mutations	  and	  so	  our	  aim	  was	  to	  identify	  early	  (common	  ‘trunk’)	  epigenetic	  events.	  	  Analysis	  of	  the	  methylation	  distributions	  for	  all	  assayed	  CpGs	  revealed	  that	  global	  methylation	  profiles	  were	  similar	  between	  tumour	  and	  benign	  prostate	  samples	  (Spearman’s	  rank	  correlation	  of	  tumour	  versus	  benign	  methylation	  profiles	  0.94-­‐1.00;	  
Supplementary	  Figure	  1b-­‐e).	  	  A	  recent	  study	  highlighted	  eight	  genomic	  loci	  that	  showed	  differential	  methylation	  in	  a	  series	  of	  unmatched	  tumour	  and	  benign	  prostate	  samples	  (i.e.	  from	  different	  individuals),	  a	  subset	  of	  which	  were	  proposed	  as	  molecular	  markers	  to	  support	  pathological	  diagnosis	  of	  biopsies	  
(Paziewska	  et	  al.	  2014).	  	  We	  assessed	  the	  reproducibility	  and	  clonality	  of	  these	  eight	  differentially	  methylated	  regions	  in	  our	  cohort	  of	  cases	  with	  multiple	  spatially	  separate	  tumour	  samples,	  matched	  benign	  tissue	  and	  blood	  DNA	  samples	  (Figure	  1b	  and	  Supplementary	  Figure	  1f-­‐m).	  	  	  In	  our	  cohort	  the	  promoter	  region	  of	  the	  HES5	  gene	  showed	  the	  largest	  and	  most	  consistent	  increase	  in	  methylation	  in	  tumour	  samples	  compared	  to	  matched	  normal	  tissue	  (median	  7.6-­‐fold	  increase,	  median	  variance	  =	  0.003),	  together	  with	  consistently	  low	  methylation	  in	  adjacent	  normal	  tissue	  (median	  normal	  methylation	  =	  0.08,	  median	  variance	  =	  0.0006;	  Figure	  1b-­‐d	  and	  Supplementary	  
Figure	  1f-­‐m).	  	  The	  study	  by	  Paziewska	  et	  al.	  showed	  low	  HES5	  promoter	  methylation	  in	  benign	  prostatic	  hyperplasia	  and	  hypermethylation	  in	  prostate	  tumour	  biopsies	  (Paziewska	  et	  al.	  2014).	  	  Among	  the	  other	  regions	  examined	  we	  found	  that	  tumour	  methylation	  at	  the	  ITGB2	  and	  mir10B	  loci	  showed	  no	  difference	  with	  matched	  benign	  tissue,	  the	  APC	  locus	  showed	  variable	  differences	  between	  tumour	  and	  matched	  benign	  and	  the	  remaining	  four	  loci	  (RARB,	  C5orf4,	  TACC2	  and	  DGKZ)	  showed	  increased	  methylation	  in	  tumour	  versus	  matched	  benign	  samples,	  although	  to	  a	  lesser	  extent	  than	  the	  HES5	  locus	  (Figure	  1b-­‐d	  and	  Supplementary	  Figure	  1f-­‐m).	  The	  tumour-­‐specific	  methylation	  changes	  at	  the	  HES5	  promoter	  were	  consistent	  within	  and	  between	  cases	  and	  comparable	  to	  the	  hypermethylation	  observed	  at	  the	  GSTP1	  gene	  (Figure	  1d-­‐e),	  which	  is	  invariably	  silenced	  in	  prostate	  cancer	  and	  has	  been	  extensively	  studied	  (Lee	  et	  al.	  1994).	  	  These	  consistent	  methylation	  changes	  at	  the	  HES5	  promoter	  appear	  to	  be	  locus	  specific,	  as	  highlighted	  by	  the	  similarity	  of	  global	  methylation	  profiles	  (Supplementary	  Figure	  1b-­‐e)	  and	  the	  absence	  of	  consistent	  changes	  in	  DNA	  methylation	  at	  other	  genomic	  loci	  across	  spatially	  separated	  tumour	  samples	  from	  the	  same	  patient	  (Supplementary	  Figure	  2).	  	  Therefore	  using	  our	  cohort	  of	  cases	  with	  multiple	  tumour	  foci	  and	  matched	  benign	  samples	  we	  found	  that	  hypermethylation	  at	  the	  HES5	  promoter	  region	  was	  observed	  across	  tumour	  samples	  from	  all	  patients	  and	  in	  all	  spatially	  separated	  tumour	  foci	  from	  the	  same	  patient.	  	  The	  homogenous	  hypermethylation	  of	  the	  HES5	  promoter	  across	  genetically	  heterogeneous	  tumour	  cores	  is	  consistent	  with	  this	  being	  an	  early	  event	  in	  tumourigenesis	  (Figure	  1c	  and	  Supplementary	  Figure	  1m).	  	  	  	  
HES5	  promoter	  methylation	  is	  a	  recurrent	  event	  in	  prostate	  tumours	  To	  assess	  the	  frequency	  of	  HES5	  hypermethylation	  in	  prostate	  cancer	  we	  performed	  targeted	  bisulfite	  sequencing	  of	  the	  HES5	  promoter	  in	  a	  separate	  cohort	  of	  39	  matched	  tumour	  and	  adjacent	  benign	  samples.	  	  This	  analysis	  included	  60	  CpGs	  in	  the	  HES5	  promoter	  and	  gave	  a	  median	  sequencing	  coverage	  of	  786x	  (Supplementary	  Figure	  3).	  	  	  This	  analysis	  provided	  a	  comprehensive	  view	  of	  DNA	  methylation	  across	  the	  HES5	  gene	  promoter,	  in	  contrast	  to	  the	  4	  CpGs	  assessed	  using	  methylation	  arrays	  and	  a	  narrow	  genomic	  window	  in	  a	  previous	  study	  (Paziewska	  et	  al.	  2014).	  	  Benign	  samples	  showed	  hypomethylation	  across	  the	  entire	  HES5	  promoter,	  whereas	  matched	  tumour	  samples	  had	  consistent	  hypermethylation	  across	  all	  60	  CpGs	  assayed	  (Figure	  
2a-­‐b	  and	  Supplementary	  Figure	  4).	  	  This	  pattern	  of	  hypomethylation	  in	  benign	  tissue	  and	  hypermethylation	  in	  tumours	  was	  consistent	  in	  38/39	  matched	  
tumour	  normal	  pairs	  	  (97%	  at	  p<0.05,	  Wilcox	  test;	  Figure	  2c).	  	  In	  the	  single	  discordant	  sample	  pair	  there	  was	  increased	  methylation	  in	  the	  matched	  benign	  sample	  that	  was	  maintained	  in	  the	  tumour	  (median	  methylation	  20.7	  and	  15.4,	  respectively;	  Supplementary	  Figure	  4),	  consistent	  with	  either	  a	  pre-­‐transformation	  change	  in	  this	  single	  case	  or	  tumour	  contamination	  of	  this	  normal	  tissue	  core.	  	  	  	  We	  also	  assessed	  HES5	  methylation	  in	  an	  additional	  prostate	  cancer	  patient	  cohort	  using	  publicly	  available	  methylation	  array	  data	  (n=304	  tumours,	  n=49	  matched	  normal	  samples)	  (Weinstein	  et	  al.	  2013).	  	  In	  this	  second	  validation	  cohort	  we	  again	  observed	  hypermethylation	  in	  tumours	  and	  hypomethylation	  in	  benign	  samples	  (42/49	  pairs,	  86%	  at	  p<0.05,	  Wilcox	  test;	  Figure	  2d-­‐e).	  	  Receiver	  operating	  characteristic	  (ROC)	  curve	  analysis	  for	  these	  two	  geographically	  distinct	  validation	  cohorts	  run	  on	  different	  platforms	  revealed	  high	  sensitivity	  and	  specificity	  (PPV=0.92,	  AUC>0.9,	  Figure	  2f).	  	  These	  results	  clearly	  demonstrate	  that	  in	  addition	  to	  being	  an	  early	  event	  in	  prostate	  tumourigenesis	  HES5	  methylation	  is	  a	  highly	  recurrent	  event	  in	  prostate	  cancer,	  suggesting	  potential	  as	  a	  specific	  disease	  marker	  and	  an	  early	  acquired	  (or	  selected)	  event	  in	  prostate	  tumourigenesis.	  	  
HES5	  is	  silenced	  in	  prostate	  cancer	  cells	  and	  demethylation	  restores	  expression	  Consistent	  with	  observations	  in	  human	  tumours	  we	  found	  that	  LNCaP	  prostate	  cancer	  cells	  exhibit	  hypermethylation	  of	  the	  HES5	  promoter,	  in	  contrast	  to	  HES5	  hypomethylation	  in	  benign	  epithelial	  cells	  PrEC	  (Figure	  3a).	  	  The	  expression	  of	  HES5	  is	  low	  or	  undetectable	  in	  cultured	  prostate	  cancer	  cell	  lines	  and	  is	  also	  low	  in	  human	  prostate	  tumours	  (Supplementary	  Figure	  5a+c	  and	  Figure	  3d+f),	  consistent	  with	  epigenetic	  silencing	  of	  HES5	  in	  prostate	  cancer	  (Supplementary	  
Figure	  5g-­‐h).	  	  Treatment	  of	  LNCaP	  cells	  with	  the	  DNA	  demethylating	  agent	  5-­‐aza-­‐2′-­‐deoxycytidine	  caused	  de-­‐repression	  of	  the	  HES5	  gene	  (Figure	  3b),	  consistent	  with	  active	  epigenetic	  silencing	  of	  the	  HES5	  gene	  in	  prostate	  cancer	  cells.	  	  	  	  
HES5	  epigenetic	  silencing	  is	  associated	  with	  HES6	  expression	  HES5	  is	  known	  to	  play	  a	  similar	  role	  to	  HES1	  in	  developmental	  processes	  (Hatakeyama,	  et	  al.	  2004;	  Hatakeyama,	  et	  al.	  2006;	  Tateya,	  et	  al.	  2011)	  and	  both	  are	  involved	  in	  negative	  feedback	  loops	  with	  HES6	  (Fior	  and	  Henrique	  2005;	  Jacobsen,	  et	  al.	  2008),	  which	  antagonizes	  the	  activity	  of	  HES1	  and	  HES5	  (Bae,	  et	  al.	  2000;	  Salama-­‐Cohen,	  et	  al.	  2005).	  	  Of	  note	  HES6	  was	  recently	  reported	  to	  play	  an	  important	  functional	  role	  in	  prostate	  cancer	  enhancing	  oncogenic	  signaling	  through	  the	  AR	  (Ramos-­‐Montoya	  et	  al.	  2014).	  	  Although	  a	  rare	  HES6	  gene	  fusion	  has	  been	  reported	  (Annala,	  et	  al.	  2014)	  no	  molecular	  mechanism	  has	  been	  found	  for	  the	  frequent	  up-­‐regulation	  of	  HES6	  in	  prostate	  cancer.	  	  In	  prostate	  cancer	  cells	  de-­‐repression	  of	  HES5	  with	  the	  demethylating	  agent	  5-­‐aza-­‐2ʹ′-­‐deoxycytidine	  resulted	  in	  a	  delayed	  down-­‐regulation	  of	  HES6	  (Figure	  3c),	  consistent	  with	  HES5	  repression	  of	  HES6.	  	  We	  also	  observed	  an	  inverse	  relationship	  between	  HES5	  and	  HES6	  expression	  in	  a	  series	  of	  primary	  tumours	  compared	  to	  benign	  prostate	  samples,	  where	  HES5	  expression	  decreased	  and	  HES6	  expression	  increased	  in	  tumour	  versus	  benign	  prostate	  samples	  (Figure	  3d-­‐e).	  	  	  In	  our	  cohort	  of	  multiple	  spatially	  separated	  tumour	  samples	  we	  found	  that	  HES5	  
expression	  was	  decreased	  in	  tumour	  cores	  compared	  to	  matched	  benign	  tissue	  and	  that	  HES6	  was	  also	  increased	  in	  some	  of	  those	  tumour	  cores,	  consistent	  with	  HES5	  silencing	  in	  tumourigenesis	  and	  additional	  mechanisms	  regulating	  HES6	  expression	  (Supplementary	  Figure	  5e-­‐f).	  	  However,	  we	  found	  no	  evidence	  of	  a	  correlation	  between	  HES5	  methylation	  and	  expression	  in	  a	  larger	  series	  of	  tumours	  (n=39),	  nor	  between	  HES5	  and	  HES6	  expression	  in	  this	  tumour	  cohort	  (Figure	  3f).	  	  This	  lack	  of	  correlation	  may	  at	  least	  in	  part	  be	  explained	  by	  the	  low	  or	  absent	  expression	  of	  HES5	  in	  prostate	  tumour	  samples	  (Figure	  2	  and	  Figure	  
3d+f)	  confounding	  such	  correlative	  analysis.	  	  Indeed	  we	  found	  that	  HES5	  expression	  appeared	  to	  be	  low	  and	  showed	  little	  variation	  in	  this	  series	  of	  39	  prostate	  tumours	  (Figure	  3f).	  The	  few	  samples	  that	  had	  slightly	  higher	  HES5	  expression	  also	  had	  low	  HES6	  expression	  (Figure	  3f),	  which	  although	  not	  compelling	  alone	  is	  consistent	  with	  our	  other	  data	  supporting	  an	  inverse	  relationship	  between	  HES5	  and	  HES6	  in	  addition	  to	  highlighting	  the	  recurrent	  silencing	  of	  HES5	  in	  tumourigenesis.	  	  	  	  There	  are	  no	  successful	  HES5	  genomic	  binding	  data	  nor	  chromatin	  immunoprecipitation	  grade	  antibodies	  for	  HES5	  therefore	  we	  could	  not	  assess	  direct	  binding	  of	  HES5	  at	  the	  HES6	  gene	  locus	  (Yan	  et	  al.	  2013).	  	  However,	  the	  preferred	  consensus	  DNA	  binding	  sequence	  of	  HES5	  has	  been	  determined	  experimentally	  (Yan	  et	  al.	  2013)	  and	  we	  found	  strong	  HES5	  consensus	  sites	  in	  and	  around	  the	  HES6	  gene	  (Supplementary	  Figure	  5i-­‐k).	  	  Taken	  together	  our	  observations	  of	  (1)	  the	  inverse	  correlation	  between	  HES5	  and	  HES6	  in	  cancer	  cells	  treated	  with	  5-­‐aza-­‐2′-­‐deoxycytidine,	  (2)	  their	  inverse	  correlation	  in	  tumour-­‐normal	  comparisons	  and	  (3)	  strong	  consensus	  HES5	  binding	  sites	  at	  the	  HES6	  gene	  locus	  suggests	  that	  HES5	  may	  repress	  HES6	  in	  prostate	  epithelial	  cells.	  	  The	  ubiquitous	  HES5	  silencing	  in	  tumours	  cells	  may	  therefore	  potentiate	  (or	  de-­‐repress)	  HES6	  expression	  in	  prostate	  tumours.	  	  	  
ERG	  and	  HES6	  expression	  show	  an	  inverse	  relationship	  Despite	  the	  early	  and	  frequent	  silencing	  of	  HES5	  in	  prostate	  cancer	  we	  observed	  variable	  expression	  of	  the	  HES5	  transcriptional	  target	  HES6	  in	  prostate	  tumour	  samples	  (Fior	  and	  Henrique	  2005)	  (Figure	  3f	  and	  Supplementary	  Figure	  5f),	  prompting	  us	  to	  investigate	  other	  factors	  that	  may	  regulate	  HES6	  expression	  in	  prostate	  tumour	  cells.	  	  We	  found	  that	  variations	  in	  HES6	  expression	  showed	  an	  inverse	  relationship	  with	  expression	  of	  the	  frequently	  rearranged	  ERG	  gene	  in	  prostate	  tumours,	  highlighted	  by	  an	  inverse	  correlation	  (r=-­‐0.28)	  and	  mutual	  exclusivity	  of	  HES6	  and	  ERG	  expression	  (i.e.	  no	  samples	  have	  both	  high	  ERG	  and	  HES6	  expression,	  Figure	  3g	  left	  panel).	  	  This	  inverse	  relationship	  is	  illustrated	  clearly	  by	  the	  increasing	  difference	  between	  ERG	  and	  HES6	  at	  higher	  levels	  of	  expression	  (i.e.	  divergence	  from	  zero	  with	  increasing	  expression,	  Figure	  3g	  
right	  panel).	  	  	  	  
ERG	  and	  HES1	  expression	  show	  a	  positive	  correlation	  In	  contrast	  the	  other	  major	  HES6	  antagonist	  HES1	  (Bae	  et	  al.	  2000;	  Hatakeyama	  et	  al.	  2004;	  Hatakeyama	  et	  al.	  2006;	  Jacobsen	  et	  al.	  2008)	  showed	  a	  strong	  positive	  correlation	  with	  ERG	  expression	  (r=0.65;	  Figure	  3h),	  suggesting	  an	  ERG-­‐HES1-­‐HES6	  transcriptional	  network	  in	  ERG-­‐fusion	  positive	  prostate	  cancer	  cells	  (Figure	  3g-­‐i).	  	  In	  support	  of	  this	  prediction	  we	  found	  evidence	  for	  extensive	  ERG	  binding	  at	  the	  HES1	  gene	  locus	  (Figure	  4f)	  and	  also	  confirmed	  the	  
previously	  reported	  AR	  binding	  sites	  upstream	  of	  the	  HES6	  gene	  (Ramos-­‐Montoya	  et	  al.	  2014)	  by	  using	  multiple	  data	  sets	  (Figure	  4g).	  	  	  
A	  transcriptional	  network	  involving	  HES5,	  AR,	  ERG	  and	  HES6	  Combining	  our	  observations	  of	  HES5	  silencing	  in	  prostate	  cancer	  with	  expression	  correlations	  in	  prostate	  tissue,	  DNA	  binding	  profiles	  for	  ERG	  and	  the	  AR	  and	  published	  transcriptional	  links	  (i.e.	  between	  HES5-­‐HES6	  (Fior	  and	  Henrique	  2005),	  HES1-­‐HES6	  (Jacobsen	  et	  al.	  2008),	  reciprocal	  HES6-­‐HES1/5	  negative-­‐feedback	  (Bae	  et	  al.	  2000;	  Hatakeyama	  et	  al.	  2006;	  Salama-­‐Cohen	  et	  al.	  2005)	  and	  AR-­‐HES6	  (Ramos-­‐Montoya	  et	  al.	  2014))	  we	  constructed	  models	  of	  putative	  gene	  expression	  networks	  in	  benign	  prostate,	  prostate	  cancer	  and	  prostate	  cancer	  harboring	  ERG-­‐rearrangements	  (Figure	  3j).	  	  In	  this	  model	  we	  predict	  that	  [i]	  HES5	  expression	  in	  benign	  epithelial	  cells	  contributes	  to	  HES6	  repression	  and	  [ii]	  HES5	  promoter	  methylation	  and	  silencing	  in	  prostate	  tumours	  potentiates	  AR	  activation	  of	  HES6	  to	  start	  an	  oncogenic	  feed-­‐forward	  transcriptional	  signaling	  network	  (Figure	  3j).	  	  Finally	  our	  model	  suggests	  that	  in	  tumour	  cells	  harbouring	  an	  ERG	  gene	  fusion	  [iii]	  AR	  activation	  of	  the	  ERG	  fusion	  gene	  creates	  a	  dynamic	  negative	  feedback	  loop	  impacting	  on	  both	  the	  AR	  and	  HES6,	  creating	  a	  more	  complex	  transcriptional	  network	  (Figure	  3j).	  	  Negative	  feedback	  loops	  are	  common	  motifs	  in	  biological	  networks	  and	  have	  been	  shown	  to	  increase	  robustness	  and	  speed-­‐up	  response	  times	  of	  transcriptional	  circuits	  (Austin,	  et	  al.	  2006;	  Nevozhay,	  et	  al.	  2009;	  Rosenfeld,	  et	  al.	  2002;	  Shen-­‐Orr,	  et	  al.	  2002).	  	  Therefore	  our	  model	  may	  highlight	  a	  previously	  unknown	  signaling	  node	  in	  ERG-­‐positive	  tumours	  that	  may	  increase	  the	  robustness	  and	  response-­‐rates	  of	  key	  pathways	  in	  prostate	  cancer.	  	  
ERG-­‐fusion	  status	  affects	  HES1	  and	  HES6	  regulation	  by	  the	  AR	  We	  tested	  the	  putative	  AR-­‐HES6	  and	  AR-­‐ERG-­‐HES1-­‐HES6	  transcriptional	  networks	  in	  AR-­‐positive	  prostate	  cancer	  cells	  with	  and	  without	  TMPRSS2-­‐ERG	  gene	  fusions	  (VCaP	  and	  LNCaP,	  respectively;	  Figure	  4).	  	  	  Using	  an	  androgen	  stimulation	  time-­‐course	  we	  were	  able	  to	  both	  track	  changes	  in	  gene	  expression	  and	  map	  their	  dynamics	  in	  prostate	  cancer	  cells	  with	  and	  without	  AR-­‐regulated	  ERG-­‐fusion	  expression	  following	  AR	  stimulation	  (Massie	  et	  al.	  2011;	  Tomlins	  et	  al.	  2005).	  	  We	  observed	  early	  up-­‐regulation	  of	  the	  known	  AR	  target	  gene	  TMPRSS2	  in	  both	  ERG-­‐fusion	  positive	  and	  ERG-­‐fusion	  negative	  cells	  in	  response	  to	  androgen	  stimulation	  (Figure	  4a),	  while	  ERG	  induction	  only	  occurred	  in	  TMPRSS2-­‐ERG	  fusion	  positive	  cells	  (Supplementary	  Figure	  7a).	  	  Consistent	  with	  its	  epigenetic	  silencing	  we	  found	  low	  expression	  and	  no	  change	  in	  HES5	  expression	  in	  either	  cell	  type	  (Supplementary	  Figure	  7b).	  	  HES1	  expression	  was	  not	  significantly	  changed	  in	  ERG-­‐fusion	  negative	  cells	  but	  showed	  strong	  androgen	  induction	  in	  ERG-­‐fusion	  positive	  cells	  (Figure	  4b).	  	  HES6	  expression	  was	  increased	  in	  ERG-­‐fusion	  negative	  cells	  but	  was	  down-­‐regulated	  in	  ERG-­‐fusion	  positive	  cells	  (Figure	  4c).	  	  Defining	  the	  timing	  of	  gene	  expression	  changes	  (‘change–points’)	  for	  these	  genes	  in	  ERG-­‐fusion	  positive	  cells	  shows	  that	  the	  sequence	  of	  events	  is:	  (1)	  TMPRSS2-­‐ERG	  up-­‐regulation;	  (2)	  HES1	  up-­‐regulation;	  (3)	  HES6	  down-­‐regulation	  (Figure	  4e).	  	  These	  data	  show	  that	  HES1	  is	  only	  induced	  by	  androgen	  signaling	  in	  ERG-­‐fusion	  positive	  cells	  and	  that	  induction	  precedes	  HES6	  repression.	  	  This	  transcriptional	  data	  is	  supported	  by	  genome-­‐wide	  binding	  profiles	  showing	  that	  the	  AR	  is	  recruited	  to	  the	  HES6	  gene	  locus	  
(Figure	  4g)	  but	  not	  to	  the	  HES1	  gene	  locus	  in	  ERG-­‐fusion	  negative	  cells	  (Figure	  
4f).	  	  However,	  in	  ERG-­‐fusion	  positive	  cells	  ERG	  binding	  is	  widespread	  at	  the	  HES1	  locus	  (Figure	  4f),	  consistent	  with	  direct	  ERG	  regulation	  of	  the	  HES1	  gene.	  	  	  	  	  
HES1	  expression	  is	  dependent	  on	  ERG	  	  To	  test	  this	  further	  we	  looked	  at	  the	  expression	  of	  HES1	  following	  ERG	  knockdown	  in	  VCaP	  cells	  (Mounir,	  et	  al.	  2014)	  (Figure	  4h	  and	  Supplementary	  
Figure	  6b-­‐c)	  and	  found	  that	  HES1	  expression	  was	  dependent	  on	  the	  expression	  of	  ERG	  (Figure	  4i	  and	  Supplementary	  Figure	  6d-­‐e),	  further	  supporting	  our	  model.	  	  In	  addition	  to	  the	  timing	  of	  expression	  changes	  in	  response	  to	  androgen	  stimulation	  these	  data	  support	  an	  AR-­‐ERG-­‐HES1-­‐HES6	  transcriptional	  network	  in	  ERG-­‐fusion	  positive	  prostate	  cancer	  cells.	  	  While	  in	  ERG-­‐fusion	  negative	  cells	  a	  simpler	  AR-­‐HES6	  network	  seems	  to	  occur.	  	  In	  each	  case	  these	  transcriptional	  networks	  may	  have	  been	  preceded	  (and	  potentiated)	  by	  HES5	  epigenetic	  silencing	  in	  early	  tumourigenesis.	  	  	  	  
Discussion	  Our	  data	  are	  consistent	  with	  an	  early	  role	  in	  prostate	  tumourigenesis	  for	  promoter-­‐wide	  hypermethylation	  of	  HES5,	  supported	  by	  the	  very	  high	  frequency	  of	  this	  epigenetic	  change	  and	  our	  observation	  that	  this	  was	  a	  common	  alteration	  in	  a	  series	  of	  multi-­‐focal	  tumours.	  	  	  While	  the	  functional	  role	  of	  HES5	  methylation	  in	  prostate	  tumourigenesis	  is	  yet	  to	  be	  determined	  we	  found	  that	  demethylation	  resulted	  in	  down-­‐regulation	  of	  the	  HES5	  target	  gene	  HES6,	  which	  has	  recently	  been	  shown	  to	  drive	  progression	  in	  prostate	  cancer	  via	  the	  androgen	  receptor	  (Ramos-­‐Montoya	  et	  al.	  2014).	  	  Therefore	  we	  speculate	  that	  one	  potential	  effector	  mechanism	  of	  HES5	  silencing	  could	  be	  de-­‐repression	  of	  HES6	  that	  in	  turn	  enhances	  AR	  regulation	  of	  key	  oncogenic	  targets,	  contributing	  to	  transformation	  and/or	  priming	  cells	  for	  subsequent	  acquisition	  of	  aggressive	  phenotypes.	  	  In	  addition	  HES5	  has	  established	  roles	  in	  tissue	  patterning	  during	  development	  (Hatakeyama	  et	  al.	  2004;	  Tateya	  et	  al.	  2011),	  with	  HES5	  null	  cells	  promoting	  an	  imbalance	  in	  intestinal	  and	  neural	  stem	  cell	  fate	  choices	  resulting	  from	  defective	  NOTCH	  signaling	  (Sancho,	  et	  al.	  2013).	  	  Intriguingly	  defective	  NOTCH	  signaling	  has	  recently	  been	  shown	  to	  drive	  clonal	  expansions	  of	  P53	  mutant	  cells	  (Alcolea,	  et	  al.	  2014),	  raising	  the	  possibility	  that	  HES5	  silencing	  early	  in	  prostate	  tumourogenesis	  might	  drive	  clonal	  expansions	  and	  contribute	  to	  the	  ‘field	  effect’	  observed	  in	  prostate	  tumours	  (Bostwick,	  et	  al.	  1998;	  Hanson,	  et	  al.	  2006;	  Mehrotra,	  et	  al.	  2008).	  	  However,	  these	  and	  other	  downstream	  consequences	  of	  the	  early	  and	  common	  epigenetic	  silencing	  of	  HES5	  will	  require	  careful	  dissection	  in	  future	  studies.	  	  It	  is	  intriguing	  that	  this	  HES5-­‐HES6/AR-­‐HES6	  transcriptional	  network	  is	  affected	  by	  TMPRSS2-­‐ERG	  gene	  fusion	  status.	  	  While	  the	  functional	  consequences	  of	  this	  remain	  to	  be	  explored,	  the	  implication	  of	  both	  AR	  and	  ERG	  oncogenenic	  signaling	  axes	  provides	  further	  weight	  for	  the	  importance	  of	  the	  HES	  transcriptional	  network	  in	  prostate	  cancer.	  	  Future	  studies	  will	  need	  to	  include	  over-­‐expression	  of	  HES5	  in	  prostate	  cancer	  cells	  to	  establish	  the	  direct	  consequences	  on	  HES6	  and	  AR	  signaling,	  as	  well	  as	  the	  phenotypic	  consequences	  of	  bypassing	  HES5	  silencing.	  	  In	  addition	  depletion	  of	  HES5	  in	  5-­‐aza-­‐2′-­‐deoxycytidine	  treated	  
prostate	  cancer	  cells	  (both	  ERG-­‐positive	  and	  ERG-­‐negative)	  will	  allow	  an	  assessment	  of	  de-­‐repression	  of	  the	  endogenous	  HES5	  locus	  on	  gene	  expression	  and	  cellular	  phenotypes.	  	  Finally	  future	  studies	  should	  also	  address	  the	  mechanisms	  upstream	  of	  HES5	  silencing,	  the	  high	  frequency	  of	  which	  would	  be	  consistent	  with	  either	  a	  strong	  selective	  pressure	  or	  a	  targeted	  silencing	  of	  HES5,	  for	  example	  via	  loss	  of	  GCM	  as	  described	  in	  neural	  stem	  cells	  (Hitoshi,	  et	  al.	  2011).	  	  This	  report	  highlights	  HES5	  silencing	  as	  an	  early	  and	  frequent	  event	  in	  prostate	  tumourigenesis	  that	  may	  serve	  as	  a	  useful	  biomarker	  or	  as	  a	  starting	  point	  for	  preventive	  medicine	  or	  targeted	  intervention	  strategies.	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Figure	  1	  	  	  HES5	  promoter	  methylation	  is	  an	  early	  event	  in	  prostate	  tumourigenesis.	  	  (A)	  Representation	  of	  sections	  through	  four	  cancerous	  prostates	  from	  which	  multiple	  tumour	  cores	  (T1-­‐T5)	  and	  adjacent	  benign	  cores	  (N1)	  were	  taken	  for	  methylation	  analysis.	  Regions	  in	  purple	  indicate	  histologically	  malignant	  foci	  and	  different	  shades	  of	  purple	  indicate	  tumour	  foci	  that	  appeared	  unconnected	  in	  3D-­‐sectioning.	  	  Sample	  keys	  provided	  are	  ICGC	  Prostate	  UK	  IDs.	  	  (B)	  Heatmap	  showing	  the	  median	  tumour	  over	  benign	  methylation	  changes	  at	  regions	  in	  the	  promoter	  regions	  of	  eight	  candidate	  genes.	  	  (C)	  Boxplots	  showing	  the	  methylation	  status	  at	  the	  promoter	  region	  of	  HES5	  in	  the	  cohort	  of	  prostate	  tumours	  with	  multiple	  tissue	  cores,	  adjacent	  benign	  and	  blood	  DNA	  samples.	  	  Boxplots	  depict	  quartiles	  for	  probes	  within	  promoter	  region	  genomic	  windows,	  error	  bars	  denote	  95%	  CI	  and	  data	  points	  are	  shown	  for	  values	  outside	  95%	  CIs.	  	  (D-­‐E)	  Genomic	  views	  of	  DNA	  methylation	  in	  tumour	  cores	  compared	  to	  adjacent	  benign	  tissue	  for	  (D)	  the	  HES5	  gene	  promoter	  region	  and	  (E)	  the	  methylation	  positive	  control	  GSTP1	  gene	  promoter.	  	  Plots	  show	  the	  methylation	  profiles	  from	  multiple	  tumour	  foci	  for	  Case-­‐006,	  data	  are	  presented	  as	  log2	  ratio	  of	  tumour	  over	  benign.	  	  Gene	  promoters	  and	  orientation	  are	  annotated	  at	  the	  top	  of	  each	  plot.	  
	  
Figure	  2	  	  Validation	  of	  HES5	  promoter	  methylation	  as	  a	  common	  event	  in	  two	  additional	  independent	  prostate	  cancer	  cohorts.	  	  (A)	  CpG	  methylation	  summary	  of	  the	  HES5	  promoter	  as	  determined	  by	  bisulfite	  sequencing	  from	  a	  representative	  tumour-­‐normal	  pair.	  	  Each	  column	  represents	  one	  CpG	  assayed	  (n=60),	  red	  and	  blue	  stacked	  bars	  represent	  the	  proportion	  of	  methylated	  and	  unmethylated	  reads,	  respectively,	  at	  each	  CpG.	  	  Column	  widths	  are	  proportional	  to	  sequencing	  coverage	  (median=786x).	  (B)	  Scatter	  plot	  summary	  of	  HES5	  promoter	  methylation	  for	  39	  tumour-­‐normal	  pairs.	  	  (C)	  Histogram	  summary	  of	  significance	  testing	  for	  increased	  HES5	  promoter	  methylation	  in	  tumour	  vs	  normal	  sample	  pairs	  (n=39	  pairs	  from	  panel-­‐C;	  paired	  Wilcox	  rank	  sum	  test;	  -­‐log2	  p-­‐values	  are	  plotted	  to	  visualise	  distributions).	  	  (D)	  Boxplot	  summary	  of	  HES5	  promoter	  methylation	  for	  304	  tumour	  and	  49	  benign	  prostate	  samples	  on	  Illumina	  450k	  arrays	  (TCGA	  data).	  	  (E)	  Histogram	  summary	  of	  significance	  testing	  for	  increased	  HES5	  promoter	  methylation	  in	  TCGA	  tumour	  vs	  normal	  sample	  pairs	  (n=49	  pairs	  from	  panel-­‐E;	  paired	  Wilcox	  rank	  sum	  test;	  -­‐log2	  p-­‐values	  are	  plotted	  to	  visualise	  distributions).	  (F)	  ROC	  curve	  for	  HES5	  promoter	  methylation	  using	  data	  from	  bisulfite	  sequencing	  of	  39	  tumour	  normal	  pairs	  (A-­‐C)	  and	  methylation	  array	  profiling	  of	  49	  tumour	  normal	  pairs	  (D-­‐E).	  	  
Figure	  3	  	  HES5	  expression	  is	  repressed	  by	  methylation	  in	  prostate	  tumour	  cells	  and	  shows	  an	  inverse	  trend	  with	  HES6	  expression.	  (A)	  Boxplot	  showing	  methylation	  status	  of	  the	  HES5	  promoter	  region	  in	  LNCaP	  prostate	  cancer	  cells	  and	  PrEC	  benign	  prostate	  cells	  (triplicates	  from	  GSE34340	  and	  singletons	  from	  GSE40699).	  	  (B-­‐C)	  Expression	  of	  (B)	  HES5	  and	  (C)	  HES6	  in	  LNCaP	  prostate	  cancer	  cells	  treated	  with	  the	  demethylating	  agent	  5-­‐aza-­‐2’-­‐deoxycytidine	  (Aza-­‐dC)	  for	  24	  and	  48h	  (GSE25346).	  	  Expression	  presented	  as	  log2	  ratios	  over	  control	  untreated	  cells.	  	  (D-­‐E)	  Boxplot	  showing	  the	  expression	  of	  (D)	  HES5	  and	  its	  known	  target	  (E)	  HES6	  in	  a	  separate	  cohort	  of	  prostatic	  benign	  and	  primary	  tumour	  tissue	  (GSE3325).	  	  Boxplots	  depict	  quartiles,	  error	  bars	  denote	  95%	  CI	  and	  data	  points	  are	  shown	  for	  values	  outside	  95%	  CIs.	  	  (F-­‐I)	  Scatter	  plots	  of	  gene	  expression	  from	  clinical	  prostate	  tumours	  showing	  the	  relationship	  between	  (F)	  HES5	  and	  HES6,	  (G)	  HES6	  and	  ERG,	  (H)	  HES1	  and	  ERG,	  (I)	  HES1	  and	  HES6	  (including	  samples	  from	  the	  cohort	  shown	  in	  Figure	  2b-­‐c).	  	  Plots	  on	  the	  left	  show	  pairwise	  relationships	  between	  gene	  expression,	  dashed	  quadrant	  lines	  indicates	  the	  mid-­‐point	  of	  expression	  values	  for	  each	  gene.	  	  Plots	  on	  the	  right	  show	  the	  relationship	  between	  the	  level	  and	  difference	  in	  expression	  for	  each	  pair	  of	  genes	  (using	  median	  centered	  values	  for	  each	  gene).	  Divergence	  from	  the	  dashed	  zero	  line	  indicates	  an	  inverse	  relationship,	  red	  trend	  lines	  depict	  loess	  regression.	  	  (J)	  Simple	  models	  of	  the	  putative	  expression	  networks	  in	  benign	  prostate,	  prostate	  cancer	  and	  ERG-­‐positive	  prostate	  cancer	  involving	  the	  AR,	  HES5,	  HES6,	  ERG	  and	  HES1.	  	  Genes	  are	  depicted	  by	  thick	  horizontal	  lines,	  connecting	  lines	  depict	  transcriptional	  targets	  of	  each	  encoded	  transcription	  factor.	  	  Connectors	  with	  arrowheads	  depict	  positively	  regulated	  targets,	  while	  connectors	  with	  flat	  ends	  depict	  repressed	  targets.	  	  Genes	  shown	  in	  grey	  depict	  low/no	  expression	  in	  a	  given	  condition.	  	  On	  the	  HES5	  gene	  open	  circles	  depict	  hypomethylation	  and	  filled	  circles	  depict	  hypermethylation.	  	  ARGs	  denotes	  AR-­‐regulated	  genes.	  	  Model	  drawn	  using	  BioTapestry.	  	  
	  




















































Figure 1   HES5 promoter methylation is an early event in prostate tumourigenesis.  (A) Representation of 
sections through four cancerous prostates from which multiple tumour cores (T1-T5) and adjacent benign 
cores (N1) were taken for methylation analysis. Regions in purple indicate histologically malignant foci 
and different shades of purple indicate tumour foci which appeared unconnected in 3D-sectioning.    
(B) Heatmap showing the median tumour over benign methylation changes at regions in the promoter 
regions of eight candidate genes.  (C) Boxplots showing the methylation status at the promoter region of 
HES5 in the cohort of prostate tumours with multiple tissue cores, adjacent benign and blood DNA samples.
Boxplots depict quartiles for probes within promoter genomic windows, error bars denote 95% CI and 
data points are shown for values outside 95% CIs.  (D-E) Genomic views of DNA methylation in tumour cores
compared to adjacent benign tissue for (D) the HES5 gene promoter region and (E) the methylation positive 
control GSTP1 gene promoter.  Plots show the methylation profiles from multiple tumour foci for Case-006, 
data are presented as log2 ratio of tumour over benign.  Gene promoters and orientation are annotated at the 
















































































































































































Figure 2  Validation of HES5 promoter methylation as a common event in two additional independent  
prostate cancer cohorts.  (A) CpG methylation summary of the HES5 promoter as determined by bisulfite 
sequencing from a representative tumour-normal pair.  Each column represents one CpG assayed 
(n=60), red and blue stacked bars represent the proportion of methylated and unmethylated reads, 
respectively, at each CpG.  Column widths are proportional to sequencing coverage (median=786x). 
(B) Scatter plot summary of HES5 promoter methylation for 39 tumour-normal pairs.  (C) Histogram 
summary of significance testing for increased HES5 promoter methylation in tumour vs normal sample 
pairs (n=39 pairs from panel-C; paired Wilcox rank sum test; -log2 p-values are plotted to visualise 
distributions).  (D) Boxplot summary of HES5 promoter methylation for 304 tumour and 49 benign 
prostate samples on Illumina 450k arrays (TCGA data).  (E) Histogram summary of significance testing 
for increased HES5 promoter methylation in TCGA tumour vs normal sample pairs (n=49 pairs from 
panel-E; paired Wilcox rank sum test; -log2 p-values are plotted to visualise distributions). (F) ROC 
curve for HES5 promoter methylation using data from bisulfite sequencing of 39 tumour normal pairs 
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Figure 3  HES5 expression is repressed by methylation in prostate tumour cells and shows an inverse trend with HES6 expression. (A) Boxplot 
showing methylation status of the HES5 promoter region in LNCaP prostate cancer cells and PrEC benign prostate cells (triplicates from 
GSE34340 and singletons from GSE40699).  (B-C) Expression of (B) HES5 and (C) HES6 in LNCaP prostate cancer cells treated with the demethyl-
ating agent 5-aza-2’-deoxycytidine (Aza-dC) for 24 and 48h (GSE25346).  Expression presented as log2 ratios over control untreated cells.  (D-E) 
Boxplot showing the expression of (D) HES5 and its known target (E) HES6 in a separate cohort of prostatic benign and primary tumour tissue 
(GSE3325).  Boxplots depict quartiles, error bars denote 95% CI and data points are shown for values outside 95% CIs.  (F-I) Scatter plots of gene 
expression from clinical prostate tumours showing the relationship between (F) HES5 and HES6, (G) HES6 and ERG, (H) HES1 and ERG, (I) HES1 
and HES6 (including samples from the cohort shown in Figure 2b-c).  Plots on the left show pairwise relationships between gene expression,  
dashed quadrant lines indicates the mid-point of expression values for each gene.  Plots on the right show the relationship between the level 
and di!erence in expression for each pair of genes (using median centered values for each gene). Divergence from the dashed zero line 
indicates an inverse relationship, red trend lines depict loess regression.  (J) Simple models of the putative expression networks in benign 
prostate, prostate cancer and ERG-positive prostate cancer involving the AR, HES5, HES6, ERG and HES1.  Genes are depicted by thick horizontal 
lines, connecting lines depict transcriptional targets of each encoded transcription factor.  Connectors with arrowheads depict positively 
regulated targets, while connectors with "at ends depict repressed targets.  Genes shown in grey depict low/no expression in a given condition.  
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panels A-C).  (F-G) *HQRPLFELQGLQJSURILOHVIRU(5*(79DQGWKH$5LQSURVWDWHFHOOVDWWKH)+(6DQG*+(6JHQHORFL*HQRPLF
ELQGLQJVLWHVIRUHDFKWUDQVFULSWLRQIDFWRUDUHGHSLFWHGE\FRORXUHGKRUL]RQWDOUHFWDQJOHV0XOWLSOHGDWDVHWVDUHLQFOXGHGIRU$5ELQLQJ
SURILOHVXVLQJWKHODEHOOLQJVFKHPH¶IDFWRUVDPSOHVWXG\·LH¶$59&D3:HLHWDO·UHSUHVHQWVWKHELQGLQJSURILOHRIWKH$5LQ9&D3
FHOOVIURPWKHVWXG\RI:HLHWDO$VFDOHEDULVVKRZQDWWKHWRSWRJHWKHUZLWKFKURPRVRPDOORFDWLRQVDQGJHQHORFDWLRQVDQG
RULHQWDWLRQVDUHLQGLFDWHGDWWKHERWWRPRIHDFKSORW+,%R[SORWVVKRZLQJWKHH[SUHVVLRQRI+(5*DQG,+(6LQ9&D3FHOOVXQGHU
FRQWURORU(5*NQRFNGRZQFRQGLWLRQV*6(6LJQLILFDQFHWHVWLQJZDVSHUIRPHGXVLQJWWHVWVSYDOXHVDQQRWDWHGRQHDFKSORW
